obesity

News

Lilly points to long-lasting weight loss with orforglipron

Lilly breaks new ground for oral GLP-1 agonists with data showing it can help patients keep weight off after treatment with injectable therapies.

R&D

Unlocking the future of obesity treatment

Obesity is more than a number on the scale, it’s a complex, malignant disease linked to diabetes, cardiovascular conditions, and even certain cancers.

News

Lilly's obesity triple pulls off 29% weight loss in trial

Eli Lilly has ramped up the competition in weight-loss therapies by reporting the first pivotal data with its triple therapy retatrutide.

News

Measuring tape overlain on a dark yellow background

Pfizer's $2bn+ obesity bet, and other weight-loss news

Pfizer licenses another GLP-1 agonist, from YaoPharma, plus clinical updates from Zealand, Structure, Ascletis, Wave, and Boehringer Ingelheim.

News

Hims & Hers launches weight-loss business in UK

Hims & Hers has launched its direct-to-consumer weight-loss therapy channel in the UK, offering Wegovy, Mounjaro, and OTC option Orlos.

R&D

pharmaphorum podcast Episode 227, Punit Dhillon, Skye Bioscience

On CB1s as an alternative to GLP-1s, with Punit Dhillon

In a new pharmaphorum podcast, Punit Dhillon, CEO of Skye Bioscience, discusses CB1 inhibitor antibodies in the obesity space.

Lilly points to long-lasting weight loss with orforglipron

Unlocking the future of obesity treatment

Lilly's obesity triple pulls off 29% weight loss in trial

Pfizer's $2bn+ obesity bet, and other weight-loss news

Hims & Hers launches weight-loss business in UK

On CB1s as an alternative to GLP-1s, with Punit Dhillon

Ambros' $125m for pain disorder drug, and other financings

How to meet your physicians where they are online

obesity

Editor's Picks